Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Revisiting the Role of p53 in Prostate Cancer

Miriam Teroerde  1 , Cathleen Nientiedt  2 , Anette Duensing  3   4   5   6 , Markus Hohenfellner  3 , Albrecht Stenzinger  7 , Stefan Duensing  1   3
Simon RJ Bott  1 , Keng Lim Ng  1
, editors.
In: Prostate Cancer [Internet]. Brisbane (AU): Exon Publications; 2021 May 27. Chapter 8.
Affiliations
Free Books & Documents
Review

Revisiting the Role of p53 in Prostate Cancer

Miriam Teroerde et al.
Free Books & Documents

Excerpt

Mutations in the tumor suppressor gene TP53 are among the most common genetic aberrations in cancer. In prostate cancer, the role of mutant TP53 remains incompletely understood. Initially, mutations in TP53 were considered late events during malignant progression and associated with metastatic dissemination and castration resistance. However, recent studies report an inactivation of TP53 at an unexpectedly high frequency in primary as well as metastatic castration-naïve prostate cancer. In this chapter, we discuss the biology of p53, the relevance of TP53 mutations for prostate cancer progression and therapy resistance, and its potential role as a marker to identify patients who require more intensified treatment.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590. - DOI - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8. https://doi.org/10.1056/NEJMoa0810084. - DOI - PubMed
    1. Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol. 2013;11(1):14–23. - PMC - PubMed
    1. Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015;47(7):736–45. https://doi.org/10.1038/ng.3315. - DOI - PubMed
    1. D’Amico AV. Risk-based management of prostate cancer. N Engl J Med. 2011;365(2):169–71. https://doi.org/10.1056/NEJMe1103829. - DOI - PubMed

LinkOut - more resources